Sponsored

The biomarker testing landscape has evolved over the years, affecting how oncologists approach lung cancer.

Pancreatic cancer remains elusive with extremely low survival rates. Through better utilization of existing therapies and identifying patient subgroups, some believe we are incrementally improving patient outcomes and making more significant advances in care.

Sponsored content by AbbVie

Sponsored Content by AstraZeneca

This content was developed in collaboration with Servier Pharmaceuticals and Onc Live

Adaptive Biotechnologies OncLive Sponsored Content Q&A

Chatrick Paul of AstraZeneca shares his perspective on the mission to eradicate cancer as a leading cause of death

Our ambition is to outsmart cancer by translating our science into health. The combination of our people and heritage is a particular advantage we have in achieving this goal. Our teams are curious, bold, and driven to deliver potentially transformative medicines to patients with cancer. Our heritage of science-based precision medicine and immuno-oncology means that we can branch into synergies to bridge different aspects of cancer research, in an agile and uncompromising manner. Our research focus is on three key mechanistic pillars: oncogenic pathways; immuno-oncology (IO); and DNA damage response (DDR); and, we are developing new approaches in key tumor types in GI, GU and thoracic cancers, all areas with significant unmet treatment needs. Together, we are transforming cancer care—today and tomorrow.

Sponsored Content by Adaptive Biotechnologies

Sponsored Content by Tempus

Sponsored Content by SANOFI

Since the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in 2015, the first CD38-directed antibody to treat multiple myeloma has been used in the treatment of more than 68,000 patients in the U.S. alone.

Sponsored Content by Ipsen

Faculty from the Miami Breast Cancer Conference® discuss how to apply the RxPONDER data to clinical practice.